Study #2024-0034
A phase 1, multicenter, open-label study of SENTI-202, a selective off-the-shelf logic gated CAR NK Cell therapy, in subjects with CD33 and/or FLT3 expressing malignancies.
MD Anderson Study Status
Enrolling
Treatment Agent
SENTI-202
Description
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Study phase:
Phase I
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.